|
Andersohn F, and Edeltraut G (2009). Cardiac and Noncardiac Fibrotic Reactions Caused by Ergot-and Nonergot-Derived Dopamine Agonists. Mov Disord 24:129-133.
Andoh T, Chock PB, Murphy DL, and Chiueh CC (2005). Role of the Redox Protein Thioredoxin in Cytoprotective Mechanism Evoked by (-)-Deprenyl. Mol Pharmacol 68:1408-1414.
Antonini A, and Calandrella D (2011). Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson’s disease: implications for patients. Neuropsychiatr Dis Treat 7:297-302.
Antonini A, and Calandrella D (2011). Pharmacokinetic evaluation of pramipexole. Expert Opin. Drug Metab. Toxicol 10:1307-1314.
Antonini A, Tolosa E, Mizuno Y, Yamamoto M, and Poewe WH (2009). A reassessment of risks and benefits of dopamine agonists in Parkinson''s disease. Lancet Neurol 8:929-937.
Atkinson MJ, Sinha A , and Hass SL (2004). Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2:12.
Bainbridge JL, and Ruscin JM (2009). Challenges of Treatment Adherence in Older Patients with Parkinsons Disease. Drugs & Aging 26:145-155.
Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, and Stricker BH (2011). OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users. Neurogenetics 12:79-82.
Bezard E, Brotchie JM, and Gross CE (2001). Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci 2:577-588.
Bonuccelli U (2003). Comparing dopamine agonists in Parkinson''s disease. Curr Opin Neurol 16:S13-S19.
Brunt ER, Brooks DJ, Korczyn AD, Montastruc JL, and Stocchi F (2002). A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson''s disease not optimally controlled by L-dopa. J Neural Transm 109:489-502.
Carlsson A, Nyberg P, and Winbald B (1984). The influence of age and other factors on concentrations of monoamines in the human brain. Brain Monoamines in Normal Aging and Dementia :53-84.
Chen J, Nelson MV, and Swope DM (2008) A Pathophysiologic Approach, Seventh Edition in Pharmacotherapy (DiPiro et al. eds) p. 978-980, ACCP Lenexa Kansas
Chen RC, Chang SF, Su CL, Chen TH, Yen MF, Wu HM, Chen ZY, and Liou HH (2001). Prevalence, incidence, and mortality of PD: a door-to-door survey in Ilan county, Taiwan. Neurology 57:1679-1686.
Chiang HL, Huang YS, Chen ST, and Wu YR (2012). Are there ethnic differences in impulsive/compulsive behaviors in Parkinson’s disease? Eur J Neurol 19:494-500.
Clarke CE and Deane KD (2001). Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson''s disease. Cochrane Database. Syst Rev.
Clarke CE, Speller JM, and Clarke JA (2009). Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson’s disease. Cochrane Database. Syst Rev.
Claxton AJ, Cramer J, and Pierce C (2001). A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23:1296-1310.
Comella CL, Stebbins GT, Brown-Toms N, and Goetz CG (1994). Physical therapy and Parkinson''s disease: a controlled clinical trial. Neurology 44:376-378.
Davie CA (2008). A review of Parkinson''s disease. Br Med Bull 86:109-127.
Ehrt U, Broich K, Larsen JP, Ballard C, and Aarsland D (2009). Use of drugs with anticholinergic effect and impact on cognition in Parkinson''s disease: a cohort study. J Neurol Neurosurg Psychiatry 81:160-165.
Fahn S, Elton RL, and Committee members of the UPDRS Development (1987). The Unified Parkinson''s Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, editors. Recent developments in Parkinson''s Disease. New York: Macmillan Healthcare Information:153-163.
Ghazi-Noori S, Chung TH, and Deane K (2009). Therapies for depression in Parkinson''s disease (Review). The Cochrane Library 1:1-18 (on line publication)
Gille G, Rausch WD, Hung ST, Moldzio R, Janetzky B, Hundemer HP, Kolter T, and Reichmann H (2002). Pergolide protects dopaminergic neurons in primary culture under stress conditions. J Neural Transm 109:633-643.
Goetz CG, Blasucci L, and Stebbins GT (1999). Switching DAs in advanced Parkinson''s disease: is rapid titration preferable to slow? Neurology 52:1227-1229.
Grace AA (1991). Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 41:1-24.
Grosset KA, Bone I, and Grosset DG (2005). Suboptimal medication adherence in Parkinson''s disease. Mov Disord 20:1502-1507.
Guttman M, Kish SJ, and Furukawa Y (2003). Current concepts in the diagnosis and management of Parkinson''s disease. CMAJ 168:293-301.
Guttman M (1997). Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson''s disease. International Pramipexole-Bromocriptine Study Group. Neurology 49:1060-1065.
Hanna PA, Ratkos L, Ondo WG, and Jankovic J (2001). Switching from pergolide to pramipexole in patients with Parkinson''s disease. J Neural Transm.108:63-70.
Hauser RA, Gauger L, Anderson WM, and Zesiewicz TA (2000). Pramipexole-induced somnolence and episodes of daytime sleep. Mov Disord 15:658-663.
Hauser RA, Schapira AHV, Rascol O, Barone P, Mizuno Y, Salin L, Haaksma M, Juhel N, and Poewe W (2010). Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson''s disease. Movt Disord 25:2542-2549.
Hirsch MA, Toole T., Maitland CG, and Rider RA (2003). The effects of balance training and high-intensity resistance training on persons with idiopathic Parkinson''s disease. Arch Phys Med Rehabil 84:1109-1117.
Hoehn MM and Yahr MD (1967). Parkinsonism : onset, progression, and mortality. Neurology 17:427-442.
Hughes AJ, Daniel SE , Kilford L , and Lees AJ (1992). Accuracy of clinical diagnosis of idiopathic Parkinson''s disease. A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181-184.
Hurst H and Bolton J(2004). Assessing the clinical significance of change scores recorded on subjective outcome measures. J Manipulative Physiol Ther 27:26-35.
Jenner P(2000). Pathophysiology and biochemistry of dyskinesia: clues for the development of non-dopaminergic treatments. J Neurol 247:II43-II50.
Kaakkola S(2000). Clinical Pharmacology, Therapeutic Use and Potential of COMT Inhibitors in Parkinson''s Disease. Drugs 59:1233-1250.
Korczyn AD, Brunt ER, Larsen JP, Nagy Z, Poewe WH, and Ruggieri S (1999). A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson''s disease. The 053 Study Group. Neurology 53:364-370.
Krishnan PR, Bhatia M., and Behari M. (2003). Restless legs syndrome in Parkinson''s disease: a case-controlled study. Mov Disord 18:181-185.
Marchese R, Diverio M, Zucchi F, Lentino C, and Abbruzzese G (2000). The role of sensory cues in the rehabilitation of parkinsonian patients: a comparison of two physical therapy protocols. Mov Disord 15:879-883.
Menza MA, Golbe LI., Cody RA, and Forman NE (1993). Dopamine‐related personality traits in Parkinson''s disease. Neurology 43:505.
Miyai I, Fujimoto Y, Ueda Y, Yamamoto H, Nozaki S, Saito T, and Kang J (2000). Treadmill training with body weight support: its effect on Parkinson''s disease. Arch Phys Med Rehabil 81:849-852.
Mizuno Y, Yamamoto M, Kuno S, Hasegawa K, Hattori N, and Kagimura T (2009). Efficacy of pramipexole extended release (ER) and switching from pramipexole immediate release (IR) to ER in Japanese advanced Parkinson''s disease (PD) patients. Proceddings of the 18th WFN World Congress on Parkinson''s Disease and Related Disorders, Miami Beach, FL, USA. Poster 2.192.
Muangpaisan W, Hori Hiroyuki, and Brayne Carol (2009). Systematic Review of the Prevalence and Incidence of Parkinson’s Disease in Asia. J Epidemiol 19:281-293.
Okereke CS (2002). Role of integrative pharmacokinetic and pharmacodynamic optimization strategy in the management of Parkinson''s disease patients experiencing motor fluctuations with levodopa. J Pharm Pharmaceut Sci 5:146-161.
Olanow CW (2000). Tolcapone and Hepatotoxic Effects. Arch Neurol 57:263-267.
Olanow CW and Stocchi F(2004). COMT inhibitors in Parkinson''s disease: can they prevent and/or reverse levodopa-induced motor complications? Neurology 62:S72-S81.
Pellecchia MT, Grasso A, Biancardi LG, Squillante M, Bonavita V, and Barone P (2004). Physical therapy in Parkinson''s disease: an open long-term rehabilitation trial. J Neurol 251:595-598.
Pezzoli G, Martignoni E, Pacchetti C, Angeleri V, Lamberti P, Muratorio A, Bonuccelli U, Mari MD, Foschi N, Cossutta E, Nicoletti F, Giammona G, Canesi M, Scarlato G, Caraceni T, and Moscarelli E (1995). Dopamine agonists in the treatment of Parkinson''s disease. Neurology 45:S22-S27.
Pezzoli G, Martignoni E, Pacchetti C, Angeleri VA, Lamberti P, Muratorio A, Bonuccelli U, Mari MD, Foschi N, Cossutta E, Nicoletti F, Giammona F, Canesi M, Scarlato G, Caraceni T, and Moscarelli E (1994). Pergolide compared with bromocriptine in Parkinson''s disease: a multicenter, crossover, controlled study. Mov Disord 9:431-436.
Radad K, Gille G, and Rausch WD (2005). Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson''s disease. Pharmacological Reports 57:701-712.
Rascol O, Barone P, Hauser RA, Mizuno Y, Poewe W, Schapira AHV, Salin L, Sohr M, and Debieuvre C (2010). Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson''s disease. Mov Disord 25:2326-2332.
Reijnders J, Ehrt U, and Weber W (2008). A Systematic review of prevalence studies of depression in Parkinson''s disease. Mov Disord 23:183-189.
Rothman B, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, and Bryan L (2000). Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102:2836-2841.
Ryan M, Slevin JT, and Wells A (2000). Non-ergot dopamine agonist-induced sleep attacks. Pharmacotherapy 20:724-726.
Schapira AH, Barone P, Hauser RA, Mizuno Y, Rascol O, Busse M, Debieuvre C, Fraessdorf M, and Poewe W (2012). Patient-reported convenience of once-daily versus three-times-daily dosing during long-term studies of pramipexole in early and advanced Parkinson’s disease. Eur J Neurol :1-7.
Schapira AH, Barone P, Hauser RA, Mizuno Y , Rascol O, Busse M , Salin L, Juhel N , and Poewe W (2011). Extended-release pramipexole in advanced Parkinson disease A randomized controlled trial. Neurology 77:767-774.
Shen WW (2011). Clinical Psychopharmacology for the 21st Centrury (in Mandarin). Taipei. Ho-Chi Publishing Company.
Silber MH, Ehrenberg BL, Allen RP, Buchfuhrer MJ, Earley CJ, Hening WA, and Rye DB (2004). An algorithm for the management of restless legs syndrome. Mayo Clin Proc 79:916-922.
Stewart D, Morgan E, Burn D, Grosser D, Chaudhuri KR, MacMahon D, Needleman F, Macphee G, and Heywood P (2004). Dopamine agonist switching in Parkinson''s disease. Hosp Med 65:215-219.
Suchowersky O, Gronseth G, Perlmutter J, Reich S, Zesiewicz T, and Weiner WJ (2006). Practice parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66:976-982.
Van Den Eeden SK (2003). Incidence of Parkinson''s disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 157:1015-1022.
von Campenhausen S, Bornschein B, Wick R, Botzel K, Sampaio C, Poewe W, Oertel W, Siebert U, Berger K, and Dodel R (2005). Prevalence and incidence of Parkinson''s disease in Europe. Eur Neuropsychopharmacology 15:473-490.
Weintraub D, Moberg PJ, Duda JE, Katz IR, and Stern MB (2004). Effect of psychiatric and other nonmotor symptoms on disability in Parkinson''s disease. J Am Geriatr Soc 52:784-788.
Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, and Pezzoli G (2007). Valvular heart disease and the use of dopamine agonists for Parkinson''s disease. N Engl J Med 356:39-46.
|